- Home
- RNA
as of 01-08-2026 3:43pm EST
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.0B | IPO Year: | 2020 |
| Target Price: | $69.26 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.51 - $72.61 | Next Earning Date: | 02-26-2026 |
| Revenue: | $20,868,000 | Revenue Growth: | 106.27% |
| Revenue Growth (this year): | 57.3% | Revenue Growth (next year): | 28.41% |
AI-Powered RNA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
Chief Human Resources Officer
Avg Cost/Share
$50.15
Shares
20,000
Total Value
$1,003,058.00
Owned After
97,130
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| McCarthy Teresa | RNA | Chief Human Resources Officer | Oct 15, 2025 | Sell | $50.15 | 20,000 | $1,003,058.00 | 97,130 |
Compare RNA vs Leading Stocks
See how RNA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.